|Bid||3.9200 x 1400|
|Ask||3.9500 x 3100|
|Day's Range||3.8300 - 3.9700|
|52 Week Range||2.3500 - 5.4000|
|Beta (5Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.38|
Accuray Incorporated (NASDAQ: ARAY) will report results for its second quarter ended December 31, 2019 on Tuesday, January 28, 2020 after the market close. Management will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
Accuray Incorporated (Nasdaq: ARAY) will be discussing its business and revenue growth expectations for the next three fiscal years at the JP Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 am PACIFIC / 1:00 pm EASTERN.
Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System provided excellent disease control with low rates of toxicity in men with locally recurrent prostate cancer after previous treatment with radiation therapy. Importantly, 69 percent of men required no androgen deprivation therapy (ADT) treatment within the first five years following CyberKnife prostate SBRT. ADT, also known as "hormone therapy," is the most common treatment given for recurrent prostate cancer. However, its use is associated with unfortunate side effects including loss of libido, hot flashes, bone fractures, loss of muscle mass and physical strength, and weight gain1. The study was recently published online in the International Journal of Radiation Oncology*Biology*Physics.
We think intelligent long term investing is the way to go. But no-one is immune from buying too high. To wit, the...
Accuray Incorporated (Nasdaq: ARAY), announced today that Joshua H. Levine, president and chief executive officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 a.m. PT. The conference will be held at the Westin St. Francis Hotel in San Francisco, California. Attendance at the conference is by invitation only.
Timpanogos Cancer Services made history in Utah recently with the installation of the state's first Radixact® System, the next-generation TomoTherapy® platform. Accuray Incorporated's (NASDAQ: ARAY) Radixact System is one of the most versatile systems available, enabling the administration of radiation using a range of delivery methods including image-guided, intensity-modulated radiation therapy (IG-IMRT) and stereotactic body radiation therapy (SBRT), that provide the hospital's clinical team with the flexibility to offer a personalized and precise treatment approach to almost anyone requiring treatment with radiation.
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife® M6™ System to expand access to precise radiosurgery treatments to more of their patients. With its installation, the hospital's clinicians will have a CyberKnife System dedicated to the treatment of diseases in the brain and base of the skull, making it possible for the existing system to be used to treat more patients with tumors elsewhere in the body. The new CyberKnife System will be installed at the Stanford Neuroscience Health Center, a comprehensive facility offering integrated outpatient services in one location designed to provide more accurate diagnoses, organized care, better quality of life and improved outcomes for the patient.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
SUNNYVALE, California, Nov. 7, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) – Thailand's Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's treatment planning system RayStation® with Accuray's Radixact® Treatment Delivery System. Lopburi has a focus on innovation and has been designated a national center of excellence for cancer treatment.
SUNNYVALE, Calif. , Nov. 6, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Suzanne Winter , the company's ...
Accuray (ARAY) delivered earnings and revenue surprises of -10.00% and -4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SUNNYVALE, Calif. , Oct. 29, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2020 ended September 30, 2019 . Recent Company ...
SUNNYVALE, Calif., Oct. 21, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October 21, 2019. Ms. Winter will have global responsibility for the commercial function reporting to Accuray's President and CEO, Joshua Levine. Ms. Winter has more than 25 years of medical technology experience in senior executive roles spanning general management, commercial operations, and strategic business development across a range of healthcare industry segments, including radiology, neurology and surgery.
SUNNYVALE, Calif. , Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. ...